20:29 , Jul 6, 2018 |  BC Extra  |  Company News

Management tracks: Goldman Sachs, Acceleron

One of China's top healthcare analysts, Richard Yeh, said he is departing Goldman Sachs, where he was in global investment research for Asia Pacific. Several Asia-focused bankers and analysts, including Citigroup's Billy Cho, Bank of...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

C4X Discovery Holdings plc (LSE:C4XD) licensed to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and is eligible for up to $284...
19:07 , Mar 29, 2018 |  BC Extra  |  Company News

C4X gains after addiction deal with Indivior

C4X Discovery Holdings plc (LSE:C4XD) jumped 56p (99%) to 112.5p after licensing to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and...
20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Evotec, C4X Discovery deal

The companies partnered to develop small molecule candidates against undisclosed targets, with initial programs aimed at cancer and autoimmune diseases. C4X will retain all IP and licensing rights for nominated candidates. Evotec will provide assay...
07:00 , Sep 27, 2016 |  BC Extra  |  Company News

Management tracks

Antibody company Prothena Corp. plc (NASDAQ:PRTA) said President and CEO Dale Schenk is taking a medical leave of absence. He will remain on Prothena's board. COO Gene Kinney will lead the company in Schenk's absence....
07:00 , Sep 12, 2016 |  BC Week In Review  |  Financial News

C4X Discovery proposes placing

C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K.   Business: Computational chemistry/biology, Neurology, Endocrine/Metabolic   Date announced: 2016-09-06   Type: Placing   To be raised: Up to L5 million ($6.7 million)   Shares: 4.9 million  ...
01:25 , May 10, 2016 |  BC Extra  |  Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Company News

Adorial, C4X Discovery deal

C4X acquired fellow drug discovery company Adorial in a cash and stock deal valued at L1.7 million ($2.4 million). Adorial will receive 1.5 million shares of C4X at 106p per share and L72,000 ($99,864) in...
01:46 , Dec 2, 2015 |  BC Extra  |  Company News

Management tracks

Opthalmology company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) hired Paul Cleveland as CEO, effective Dec. 9. Cleveland was CEO at Celladon Corp. (NASDAQ:CLDN). Oncology and inflammation play Zai Laboratory Ltd. (Shanghai, China) named Qi Liu CMO. Liu...